Market Place
Sourcing Support
Marker Therapeutics & Cellipont Bioservice Collaborate for MT-601
17 Jun 2025 //
GLOBENEWSWIRE
Marker: Lymphodepletion Boosts T Cells in Lymphoma Patients
20 May 2025 //
GLOBENEWSWIRE
Marker Therapeutics to Highlight MAR-T Cells in CAR-T Panel
19 May 2025 //
GLOBENEWSWIRE
Marker Therapeutics to Present at Oncology Conference
01 Apr 2025 //
GLOBENEWSWIRE
Marker Therapeutics Reports 2024 Corporate and Financial Results
31 Mar 2025 //
GLOBENEWSWIRE
Marker Therapeutics to Present at H.C. Wainwright Conference
25 Feb 2025 //
GLOBENEWSWIRE
Marker Therapeutics Provides Clinical Update on MT-601 in Lymphoma
19 Dec 2024 //
GLOBENEWSWIRE
Marker Therapeutics Announces $16.1 Million Private Placement
19 Dec 2024 //
GLOBENEWSWIRE
Marker Awarded 9.5M Grant for MT-601 in Pancreatic Cancer
17 Dec 2024 //
GLOBENEWSWIRE
Marker to Present at 2024 Ladenburg Virtual Oncology Symposium
10 Dec 2024 //
GLOBENEWSWIRE
Marker Therapeutics to Present at Citizens JMP Hematology Summit
26 Nov 2024 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q3 2024 Financial Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q2 2024 Financial Results And Business Updates
14 Aug 2024 //
GLOBENEWSWIRE
Marker Therapeutics Gets $2M NIH Grant For MT-601 Lymphoma Study
12 Aug 2024 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q1 2024 Results, Business Updates
15 May 2024 //
GLOBENEWSWIRE
Principal Investigator from CHNMC Invited to Present Data from Marker APOLLO
08 Apr 2024 //
GLOBENEWSWIRE
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 Mar 2024 //
GLOBENEWSWIRE
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy VC
22 Mar 2024 //
GLOBENEWSWIRE
Marker Therapeutics Receives Approval from USAN Council for Neldaleucel
22 Jan 2024 //
GLOBENEWSWIRE
Marker Announces Clinical Program Updates and Pipeline Prioritization
08 Jan 2024 //
GLOBENEWSWIRE
Marker Therapeutics Announces Participation in Biotech Showcase
21 Dec 2023 //
GLOBENEWSWIRE
Marker Announces Complete Response in First Lymphoma Patient Treated with MT-601
11 Dec 2023 //
GLOBENEWSWIRE
Marker Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Marker Announces Complete Response in First Lymphoma Patient Treated with MT-601
11 Sep 2023 //
GLOBENEWSWIRE
Marker Therapeutics to Present at the H.C. Wainwright 25th Global Conference
30 Aug 2023 //
GLOBENEWSWIRE
Marker Reports Second Quarter 2023 Financial Results & Provides Business Update
14 Aug 2023 //
GLOBENEWSWIRE
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data for the MT-401
07 Aug 2023 //
GLOBENEWSWIRE
Marker Therapeutics to Participate in Roundtable with Key Opinion Leaders
26 Jul 2023 //
GLOBENEWSWIRE
EMA Grants Orphan Drug Designation for MT-401 developed by Marker
10 Jul 2023 //
GLOBENEWSWIRE
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells
26 Jun 2023 //
GLOBENEWSWIRE
Marker Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Trial
12 Jun 2023 //
GLOBENEWSWIRE
Marker Therapeutics Reports Pre-Clinical Data of its MT-601
31 May 2023 //
GLOBENEWSWIRE
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
08 May 2023 //
GLOBENEWSWIRE
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement CellReady
01 May 2023 //
GLOBENEWSWIRE
Marker Therapeutics Partners with CellReady
01 May 2023 //
CONTRACT PHARMA
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Marker Therapeutics and Lincoln Park Capital Enter into Agreement for up to $25M
13 Dec 2022 //
GLOBENEWSWIRE
Marker Therapeutics Announces FDA Clearance of IND for MT-601
22 Nov 2022 //
GLOBENEWSWIRE
Marker Awarded $2 M Grant from U.S. FDA to Support Marker’s Phase 2 MT-401
13 Sep 2022 //
GLOBENEWSWIRE
Marker to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
08 Sep 2022 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Marker Therapeutics Announces FDA Clearance of IND for MT-601 for r/r NHL
04 Aug 2022 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
13 May 2022 //
GLOBENEWSWIRE
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies
04 May 2022 //
GLOBENEWSWIRE
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
26 Apr 2022 //
GLOBENEWSWIRE
Marker Tx Reports FY 2021 Operating and Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Marker Tx to Present at Two Upcoming March Investor Conferences
07 Mar 2022 //
GLOBENEWSWIRE
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
16 Feb 2022 //
GLOBENEWSWIRE
Marker Tx Receives FDA ODD for Multi-Antigen Targeted T Cell Therapy
19 Jan 2022 //
GLOBENEWSWIRE
Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
10 Nov 2021 //
PRNEWSWIRE
Cancer Prevention and Research Institute grants $13.1M to Marker Therapeutics
19 Aug 2021 //
PRNEWSWIRE
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
12 May 2021 //
PRESS RELEASE
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
11 Mar 2021 //
PRNEWSWIRE
Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
11 Mar 2021 //
PRNEWSWIRE
Marker Announces Dosing of First Patient in Phase 2 Trial of MT-401
03 Mar 2021 //
PRNEWSWIRE
Marker Therapeutics Announces Completion of New Manufacturing Facility
13 Jan 2021 //
PRNEWSWIRE
Marker Therapeutics Announces New MFG Facility to Support Clinical DevP
30 Jun 2020 //
PRNEWSWIRE
Marker Announces New mfg Facility to Support Clinical Devp of MultiTAA
30 Jun 2020 //
PRNEWSWIRE
Marker Therapeutics Receives USAN Approval for " for MT-401
23 Jun 2020 //
PRNEWSWIRE
Marker Reports Interim Results of its MultiTAA-Specific T Cell Therapy
29 May 2020 //
PRNEWSWIRE
